Thursday, September 17, 2026
27.4 C
Bengaluru

Platforms Are Owning the Patient While Pharma Waits

The future of experimental medicine is not simply a regulatory question. It is a question about who controls access, who pays for treatment, who generates evidence, and who bears the risk.

We spend too much time debating what will happen in healthcare.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Topics

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...
spot_img

Related Articles

spot_imgspot_img